Ipsen Acquisition of Kartos Therapeutics for asset in refractory myelofibrosis minor positive

研报英文原文证据摘录

Ipsen Acquisition of Kartos Therapeutics for asset in refractory myelofibrosis minor positive

J P M O R G A N Europe Equity Research

29 June 2026

Ipsen Neutral

IPN.PA, IPN FP

Acquisition of Kartos Therapeutics for asset in Price (26 Jun 26):€162.40

refractory myelofibrosis minor positive

European Pharmaceuticals &

This morning, Ipsen announced the acquisition of Kartos Therapeutics for $450m Biotechnology

upfront and $1.3bn potential regulatory and sales milestone payments. The Richard Vosser AC

transaction adds to its oncology portfolio navtemadlin, an oral MDM2 inhibitor (44-20) 7742-6652

under investigation in patients with myelofibrosis refractory to standard of care richard.vosser@jpmorgan.com

J.P. Morgan Securities plc

ruxolitinib. We believe approximately 40% of patients have a sub-optimal

Sophia Graeff Buhl Nielsen

response to ruxolitinib within four months and this extends to the majority of

(44-20) 7742-3918

patients within two years. Navtemadlin is currently in a global Phase III trial sophia.graeffbuhlnielsen@jpmorgan.com

(POIESIS) in patients refractory to ruxolitinib, with top-line data anticipated in J.P. Morgan Securities plc

2027. Encouraging Phase 1b/2 data for the asset was presented at EHA 2023, Zain Ebrahim

demonstrating 32% of patients achieving a total symptom score improvement of (44-20) 3493-1163

at least 50% at week 24. While Ipsen anticipates near blockbuster potential for the zain.ebrahim@jpmorgan.com

asset and sees limited competition in the indication, we note that GSK’s Phase 3 J.P. Morgan Securities plc

SIMPLIFY-2 trial for momelotinib in inadequate ruxolitinib responders missed its Dhitee Goel

primary endpoint but was nonetheless approved in anaemic patients, which would (44-20) 7742-2591

dhitee.goel@jpmorgan.com